PMID- 23574727
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20151119
IS  - 1755-6686 (Electronic)
IS  - 1755-6678 (Linking)
VI  - 39
IP  - 2
DP  - 2013 Jun
TI  - Comparison of sevelamer and calcium carbonate on endothelial function and 
      inflammation in patients on peritoneal dialysis.
PG  - 82-9
LID - 10.1111/j.1755-6686.2013.12009.x [doi]
AB  - BACKGROUND: Hyperphosphataemia is a known independent risk factor for 
      cardiovascular mortality. The objective of the study was to compare the effects 
      of two phosphate binders, sevelamer carbonate and calcium carbonate on 
      endothelial function (EF) and inflammation in patients on peritoneal dialysis 
      (PD) with Type 2 diabetes mellitus (T2DM). METHODS: Fifteen subjects with 
      hyperphosphataemia discontinued all phosphate binders to undergo a two-week 
      washout and were assigned to sevelamer carbonate or calcium carbonate treatments 
      for eight weeks. After a second two-week washout period, subjects crossed over to 
      either of the alternate treatments for another eight weeks. At the beginning and 
      end of each treatment, biomarkers of EF, pro-inflammatory cytokines, serum 
      albumin, calcium, phosphate and lipids were measured. RESULTS: Sevelamer 
      carbonate significantly improved lipid profile compared with calcium carbonate. 
      Amongst the EF and pro-inflammatory biomarkers, sevelamer carbonate decreased 
      serum endothelin-1, plasminogen activator inhibitor-1, C-reactive protein and 
      interleukin-6. Both phosphate binders were effective in decreasing serum 
      phosphate but sevelamer had a positive effect on EF. CONCLUSIONS: Treatment with 
      sevelamer carbonate has beneficial effects compared with calcium carbonate in 
      decreasing inflammation and improving EF in patients with T2DM on PD.
CI  - (c) 2013 European Dialysis and Transplant Nurses Association/European Renal Care 
      Association.
FAU - Chennasamudram, Sudha P
AU  - Chennasamudram SP
AD  - Department of Pediatrics, School of Medicine, Texas Tech University Health 
      Sciences Center, Amarillo, Texas 79106, USA.
FAU - Noor, Tanjila
AU  - Noor T
FAU - Vasylyeva, Tetyana L
AU  - Vasylyeva TL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130410
PL  - United States
TA  - J Ren Care
JT  - Journal of renal care
JID - 101392167
RN  - 0 (Biomarkers)
RN  - 0 (Chelating Agents)
RN  - 0 (Cytokines)
RN  - 0 (Lipids)
RN  - 0 (Phosphates)
RN  - 0 (Polyamines)
RN  - 0 (Serum Albumin)
RN  - 9YCX42I8IU (Sevelamer)
RN  - H0G9379FGK (Calcium Carbonate)
RN  - SY7Q814VUP (Calcium)
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - Calcium/blood
MH  - Calcium Carbonate/*therapeutic use
MH  - Chelating Agents/*therapeutic use
MH  - Cross-Over Studies
MH  - Cytokines/blood
MH  - Diabetes Mellitus, Type 2/complications
MH  - Endothelial Cells/*physiology
MH  - Female
MH  - Humans
MH  - Hyperphosphatemia/etiology/*therapy
MH  - Inflammation/*physiopathology
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - *Peritoneal Dialysis
MH  - Phosphates/blood
MH  - Polyamines/*therapeutic use
MH  - Serum Albumin
MH  - Sevelamer
MH  - Treatment Outcome
EDAT- 2013/04/12 06:00
MHDA- 2014/01/31 06:00
CRDT- 2013/04/12 06:00
PHST- 2013/04/12 06:00 [entrez]
PHST- 2013/04/12 06:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - 10.1111/j.1755-6686.2013.12009.x [doi]
PST - ppublish
SO  - J Ren Care. 2013 Jun;39(2):82-9. doi: 10.1111/j.1755-6686.2013.12009.x. Epub 2013 
      Apr 10.